Y Zhao1, W You2, J Zheng3, Y Chi1, W Tang4, R Du4. 1. Department of Obstetrics and Gynecology, Liaocheng Second People's Hospital, Liaocheng, 252600, China. 2. Department of Obstetrics and Gynecology, Liaocheng People's Hospital, No. 45, Huashan Road, Development Area, Liaocheng, Shandong, 252000, China. youweizhilc@126.com. 3. Department of Obstetrics and Gynecology, Liaocheng Third People's Hospital, Liaocheng, 252000, China. 4. Central Laboratory, Liaocheng People's Hospital, Liaocheng, 252000, China.
Abstract
PURPOSE: Cervical cancer is one of the most prevalent malignancies in women worldwide. Therefore, the investigation about the molecular pathogenesis and related therapy targets of cervical cancer is an emergency. The objective of the present study is to investigate the effects of valproic acid (VPA), a histone deacetylase inhibitor, on the angiogenesis of cervical cancer. METHODS: The effects and mechanisms of VPA on in vitro angiogenesis and vascular endothelial growth factor (VEGF) expression of human cervical cancer HeLa and SiHa cells were investigated. RESULTS: Our present study reveals that 1 mM VPA can significantly inhibit the in vitro angiogenic potential and VEGF expression of human cervical cancer HeLa and SiHa cells. Further, the transcription and protein levels of hypoxia inducible factor-1α (HIF-1α), and not HIF-1β, are significantly inhibited in VPA-treated cervical cancer cells. Over expression of HIF-1α can obviously reverse VPA-induced VEGF down regulation. VPA-treatment decreases the activation of Akt and ERK1/2 in both HeLa and SiHa cells in a time-dependent manner. The inhibitor of Akt (LY 294002) or ERK1/2 (PD98059) can inhibit VEGF alone and cooperatively reinforce the suppression effects of VPA on HIF-1α and VEGF expression. CONCLUSION: Collectively, our data reveal that the inhibition of PI3K/Akt and ERK1/2 signals are involved in VPA-induced HIF-1α and VEGF suppression of cervical cancer cells.
PURPOSE:Cervical cancer is one of the most prevalent malignancies in women worldwide. Therefore, the investigation about the molecular pathogenesis and related therapy targets of cervical cancer is an emergency. The objective of the present study is to investigate the effects of valproic acid (VPA), a histone deacetylase inhibitor, on the angiogenesis of cervical cancer. METHODS: The effects and mechanisms of VPA on in vitro angiogenesis and vascular endothelial growth factor (VEGF) expression of humancervical cancer HeLa and SiHa cells were investigated. RESULTS: Our present study reveals that 1 mM VPA can significantly inhibit the in vitro angiogenic potential and VEGF expression of humancervical cancer HeLa and SiHa cells. Further, the transcription and protein levels of hypoxia inducible factor-1α (HIF-1α), and not HIF-1β, are significantly inhibited in VPA-treated cervical cancer cells. Over expression of HIF-1α can obviously reverse VPA-induced VEGF down regulation. VPA-treatment decreases the activation of Akt and ERK1/2 in both HeLa and SiHa cells in a time-dependent manner. The inhibitor of Akt (LY 294002) or ERK1/2 (PD98059) can inhibit VEGF alone and cooperatively reinforce the suppression effects of VPA on HIF-1α and VEGF expression. CONCLUSION: Collectively, our data reveal that the inhibition of PI3K/Akt and ERK1/2 signals are involved in VPA-induced HIF-1α and VEGF suppression of cervical cancer cells.
Authors: M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel Journal: EMBO J Date: 2001-12-17 Impact factor: 11.598
Authors: Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero Journal: Blood Date: 2007-06-27 Impact factor: 22.113
Authors: Mèlanie S M van Breemen; R M Rijsman; M J B Taphoorn; R Walchenbach; H Zwinkels; Charles J Vecht Journal: J Neurol Date: 2009-05-12 Impact factor: 4.849
Authors: Timothy K Byler; Dean Leocadio; Oleg Shapiro; Gennady Bratslavsky; Christopher J Stodgell; Ronald W Wood; Edward M Messing; Jay E Reeder Journal: BMC Urol Date: 2012-08-16 Impact factor: 2.264
Authors: Antonio Avallone; Maria Carmela Piccirillo; Elena Di Gennaro; Carmela Romano; Filomena Calabrese; Maria Serena Roca; Fabiana Tatangelo; Vincenza Granata; Antonio Cassata; Ernesta Cavalcanti; Nicola Maurea; Piera Maiolino; Lucrezia Silvestro; Alfonso De Stefano; Francesco Giuliani; Gerardo Rosati; Emiliano Tamburini; Pasquale Aprea; Valeria Vicario; Anna Nappi; Carlo Vitagliano; Rossana Casaretti; Alessandra Leone; Antonella Petrillo; Gerardo Botti; Paolo Delrio; Francesco Izzo; Francesco Perrone; Alfredo Budillon Journal: Ther Adv Med Oncol Date: 2020-08-11 Impact factor: 8.168
Authors: Shamini Murugavel; Antoinette Bugyei-Twum; Pratiek N Matkar; Husain Al-Mubarak; Hao H Chen; Mohamed Adam; Shubha Jain; Tanya Narang; Rawand M Abdin; Mohammad Qadura; Kim A Connelly; Howard Leong-Poi; Krishna K Singh Journal: Front Pharmacol Date: 2018-07-11 Impact factor: 5.810
Authors: Yudibeth Sixto-López; Martha Cecilia Rosales-Hernández; Arturo Contis-Montes de Oca; Leticia Guadalupe Fragoso-Morales; Jessica Elena Mendieta-Wejebe; Ana María Correa-Basurto; Edgar Abarca-Rojano; José Correa-Basurto Journal: Int J Mol Sci Date: 2020-08-16 Impact factor: 5.923